Literature DB >> 2120891

Molecular characterization and nonradioactive detection of beta-thalassemia in Malaysia.

S Fucharoen1, G Fucharoen, K Ata, S Aziz, S Hashim, K Hassan, Y Fukumaki.   

Abstract

The spectrum of beta-thalassemia mutations in Malaysia has been determined in 45 beta-thalassemia chromosomes using dot blot hybridization of the polymerase chain reaction amplified DNA and direct DNA sequencing. Eleven different molecular defects, including those previously detected in Chinese, Asian Indians, and American blacks, and a novel frameshift mutation causing beta zero-thalassemia were detected. Since this novel mutation, a T deletion in codon 15 creates a new restriction site for EcoRII enzyme; the mutation could be detected by EcoRII digestion of the appropriate amplified fragment. The results of the present study provide additional information on the molecular heterogeneity of beta-thalassemia in this population. We also demonstrated the nonradioactive detection method of the beta-thalassemia mutation based upon the digoxigenin-labeled oligonucleotide probes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120891     DOI: 10.1159/000205034

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

1.  Thalassemia intermedia phenotype resulting from rare combination of c.46delT [Codon15 (-T)] mutation of beta globin gene and HPFH3.

Authors:  Anjali J Kelkar; Anu Moses
Journal:  Clin Case Rep       Date:  2017-05-26

2.  Observational study on the current status of thalassaemia in Malaysia: a report from the Malaysian Thalassaemia Registry.

Authors:  Hishamshah Mohd Ibrahim; Zulaiha Muda; Ida Shahnaz Othman; Mohamed Najib Mohamed Unni; Kok Hoi Teh; Asohan Thevarajah; Kogilavani Gunasagaran; Gek Bee Ong; Seoh Leng Yeoh; Aisyah Muhammad Rivai; Che Hadibiah Che Mohd Razali; Nazzlin Dizana Din; Zarina Abdul Latiff; Rahman Jamal; Norsarwany Mohamad; Hany Mohd Ariffin; Hamidah Alias
Journal:  BMJ Open       Date:  2020-06-29       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.